Pedersen, J.G.; Madsen, A.T.; Gammelgaard, K.R.; Aggerholm-Pedersen, N.; Sørensen, B.S.; Øllegaard, T.H.; Jakobsen, M.R.
Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. Cancers 2020, 12, 1414.
https://doi.org/10.3390/cancers12061414
AMA Style
Pedersen JG, Madsen AT, Gammelgaard KR, Aggerholm-Pedersen N, Sørensen BS, Øllegaard TH, Jakobsen MR.
Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. Cancers. 2020; 12(6):1414.
https://doi.org/10.3390/cancers12061414
Chicago/Turabian Style
Pedersen, Jesper Geert, Anne Tranberg Madsen, Kristine Raaby Gammelgaard, Ninna Aggerholm-Pedersen, Boe Sandahl Sørensen, Trine Heide Øllegaard, and Martin Roelsgaard Jakobsen.
2020. "Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors" Cancers 12, no. 6: 1414.
https://doi.org/10.3390/cancers12061414
APA Style
Pedersen, J. G., Madsen, A. T., Gammelgaard, K. R., Aggerholm-Pedersen, N., Sørensen, B. S., Øllegaard, T. H., & Jakobsen, M. R.
(2020). Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. Cancers, 12(6), 1414.
https://doi.org/10.3390/cancers12061414